remimazolam has been researched along with Kidney-Diseases* in 1 studies
1 trial(s) available for remimazolam and Kidney-Diseases
Article | Year |
---|---|
Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment.
Remimazolam is a new benzodiazepine for procedural sedation and general anaesthesia. The aim of this study was to characterise its pharmacokinetic properties and safety in renally and hepatically impaired subjects.. Two separate trials were conducted in patients with hepatic (n=11) or renal impairment (n=11) compared with matched healthy subjects (n=9 and n=12, respectively). The hepatic impairment trial was an open-label adaptive 'Reduced Design' trial, using a single bolus of remimazolam 0.1 mg kg. Remimazolam pharmacokinetic properties were adequately described by a three-compartment, recirculatory model. Exposure in subjects with severe hepatic impairment was 38.1% higher (i.e. clearance was 38.1% lower) compared with healthy volunteers. This increase caused a slightly delayed recovery (8.0 min for healthy, 12.1 min for moderate, and 16.7 min for severe hepatic impairment). With renal impairment, plasma clearance was comparable with that measured in healthy subjects. Simulations of C. As C. Hepatic impairment trial: ClinicalTrials.gov, NCT01790607 (https://clinicaltrials.gov/ct2/show/NCT01790607). Renal impairment trial: EudraCT Number: 2014-004575-23. Topics: Adult; Benzodiazepines; Computer Simulation; Drug Monitoring; Female; Glomerular Filtration Rate; Humans; Hungary; Hypnotics and Sedatives; Injections, Intravenous; Kidney; Kidney Diseases; Liver; Liver Diseases; Male; Middle Aged; Models, Biological; Risk Assessment; Risk Factors; Severity of Illness Index; United States | 2021 |